Company Overview
| Stock Name | Canbridge-B |
|---|---|
| Stock Code | 01228 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 立足中國、專注於罕見病的生物醫藥公司,致力於研究、開發及商業化生物科技療法,產品管線包括13個藥物資產,涵蓋罕見病及罕見腫瘤適應症。 |
| Listing Date | 2021-12-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市朝陽區容創路17號時代凌宇大廈3樓301室 |
| Business Address (Hong Kong) | 香港尖沙咀廣東道15號海港城港威大廈5座16樓A131室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.canbridgepharma.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 12.18 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 12,180 |
| Par Value | To be extracted |
| Offer Period | 2021-11-30 to 2021-12-03 |
| Global Offering Shares | 56,251,000 shares |
| HK Public Offer Shares (Initial) | 5,626,000 shares (10.0%) |
| Public Offer Lots (Initial) | 5,626lots (Pool A2,813lots,Pool B2,813lots) |
| International Placing Shares (Initial) | 50,625,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 424,191,920 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 68.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 685,137,180 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 12,180 |
| 2 lots | 2,000 | HK$ 24,360 |
| 3 lots | 3,000 | HK$ 36,540 |
| 4 lots | 4,000 | HK$ 48,720 |
| 5 lots | 5,000 | HK$ 60,900 |
| 6 lots | 6,000 | HK$ 73,080 |
| 7 lots | 7,000 | HK$ 85,260 |
| 8 lots | 8,000 | HK$ 97,440 |
| 9 lots | 9,000 | HK$ 109,620 |
| 10 lots | 10,000 | HK$ 121,800 |
| 15 lots | 15,000 | HK$ 182,700 |
| 20 lots | 20,000 | HK$ 243,600 |
| 25 lots | 25,000 | HK$ 304,500 |
| 30 lots | 30,000 | HK$ 365,400 |
| 35 lots | 35,000 | HK$ 426,300 |
| 40 lots | 40,000 | HK$ 487,200 |
| 50 lots | 50,000 | HK$ 609,000 |
| 60 lots | 60,000 | HK$ 730,800 |
| 70 lots | 70,000 | HK$ 852,600 |
| 80 lots | 80,000 | HK$ 974,400 |
| 90 lots | 90,000 | HK$ 1,096,200 |
| 100 lots | 100,000 | HK$ 1,218,000 |
| 150 lots | 150,000 | HK$ 1,827,000 |
| 200 lots | 200,000 | HK$ 2,436,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 450 lots | 450,000 | HK$ 5,481,000 |
| 1,600 lots | 1,600,000 | HK$ 19,488,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.27B |
| Est. Threshold | HK$ 9.37B |
| Analysis Result | HK market cap below threshold, need +640% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 5,166,657,585 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣846.0百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 1,449 | 13,002 |
| Cost of sales | -494 | -6,154 |
| Gross profit | 955 | 6,848 |
| Other income and gains, net | 570 | 12,559 |
| Selling and distribution expenses | -28,881 | -51,008 |
| Administrative expenses | -53,619 | -77,706 |
| Net finance costs | -2,275 | -3,873 |
| Profit before tax | -219,075 | -849,443 |
| Profit for the year | -220,475 | -851,843 |
| Profit attributable to owners | -221,875 | -853,643 |
Balance Sheet
| Item | 2019 | 2020 | 2021-06 |
|---|---|---|---|
| Cash and cash equivalents | 13,863 | 350,794 | |
| Trade and bills receivables | 24,584 | 33,557 | |
| Inventories | 6,576 | 46,703 | |
| Total current assets | 37,895 | 390,945 | |
| Total assets | 88,600 | 586,258 | |
| Total current liabilities | 43,749 | 118,003 | |
| Total liabilities | 1,079,196 | 2,322,114 | |
| Total equity | -980,696 | -1,735,856 | |
| Equity attributable to owners | -970,701 | -1,716,861 | |
| Interest-bearing borrowings | 26,466 | 33,959 | 18,553 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-06 |
|---|---|---|---|
| Net cash from operating activities | -127,165 | -152,638 | |
| Net cash from investing activities | -42,409 | -164,473 | |
| Net cash from financing activities | 96,956 | 678,253 | |
| Net increase in cash | -72,607 | 373,122 | |
| Depreciation of PP&E | 1,277 | 1,426 | 953 |
| Depreciation of right-of-use assets | 2,305 | 3,462 | 2,573 |
| Amortisation of intangible assets | 13 | 12,951 | 3,775 |
| Purchase of PP&E | -1,080 | -2,571 | -2,773 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 8.9 |
|---|---|
| First Day Open | HK$ 9.8 |
| First Day Change | -26.93% |
| First Day Volume | 29094800.0 |
| First Day Turnover | 266971000.0 |
| Use of Proceeds | 1、約45.4%或274.2 百萬港元將分配用于為我們的核心產品候選藥物CAN008的現有及日后研發、CMC開發以及生產流程發展提供資金;
2、約24.0%或145.0百萬港元將分配用于為以下我們產品管線中的主要產品及候選產品提供資金;
3、約1.8%或10.9百萬港元將分配用于我們產品管線中其他產品及候選產品的現有及日后研發提供資金;
4、約12.0%或72.5百萬港元,預計用于為CAN201、CAN202及其他基因治療候選藥物的現有及日后研發提供資金;
5、16.8%或101.5百萬港元將分配用于為研發及其他一般業務用途提供資金。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (5)
Joint Lead Managers (6)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Belinda A. Termeer | 15,578,220 HKD | — | 2.27% | — | 6 months | 2022-06-10 |
| 2 | General Atlantic Singapore CP Pte. Ltd. | 38,939,460 HKD | — | 5.68% | — | 6 months | 2022-06-10 |
| 3 | Hudson Bay Master Fund LTD | 62,312,880 HKD | — | 9.09% | — | 6 months | 2022-06-10 |
| 4 | Janus Henderson Funds | 38,939,460 HKD | — | 5.68% | — | 6 months | 2022-06-10 |
| 5 | RA Capital Healthcare Fund, L.P. | 233,685,480 HKD | — | 34.11% | — | 6 months | 2022-06-10 |
| 6 | 江苏瑞华投资控股集团有限公司 | 38,939,460 HKD | — | 5.68% | — | 6 months | 2022-06-10 |
| 7 | 药明生物产业基金 | 38,939,460 HKD | — | 5.68% | — | 6 months | 2022-06-10 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 薛群 | — |
| Company Secretary | 馬倩、王承鏱 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 主要股東包括RA Capital Management, L.P.(13.14%)、藥明康德(9.51%)、CTX Pharma(6.14%)、Qiming Corporate GP IV, Ltd.(7.74%)、薛博士(全權信託3.54%、實益2.41%)等。 |
|---|




